Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for correction of hyponatremia in chronic heart failure
IRCT20191104045328N28Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyponatraemia and chronic heart failure (CHF) comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Serum sodium, Hypoglycemia and 2 more. Started Sep 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
hyponatraemiachronic heart failure (CHF)
Beyond the preview
Go deeper on IRCT20191104045328N28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191104045328N28.